Tenofovir alafenamide , a new once-daily oral prodrug of tenofovir , showed more potent anti-HIV-1 activity and higher intracellular tenofovir levels compared with tenofovir disoproxil fumarate , while maintaining lower plasma tenofovir exposure at 40 mg with good tolerability over 14 days of monotherapy .